In the following video, Motley Fool health-care analyst Max Macaluso takes a question from a Fool reader, who asks, "Albany Molecular Research (AMRI) beat earnings and raised guidance then dropped up to 19% recently. What am I missing?"
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.